2923558-68-1
Chemical Structure
Macupatide
Synonym(s): LY3532226
- CAS No.: 2923558-68-1
- Formula:C232H357N49O72
- Molecular Weight:4984.60
SMILES: O=C([C@@H](N)CC1=CC=C(O)C=C1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@](C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N3[C@H](C(N4[C@H](C(N5[C@H](C(N[C@H](C(N)=O)CO)=O)CCC5)=O)CCC4)=O)CCC3)=O)C)=O)=O)CO)=O)CO)=O)CCC2)=O)=O)C)=O)CCC(O)=O)=O)CC(C)C)=O)CC(C)C)=O)CC6=CC=NC=C6)=O)CCC(O)=O)=O)C(C)C)=O)CC7=CC=CC=C7)=O)CC(O)=O)=O)C)=O)CCC(N)=O)=O)CC8=CNC=N8)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)CC(C)C)=O)[C@H](CC)C)=O)CO)=O)CC9=CC=C(O)C=C9)=O)CC(O)=O)=O)CO)=O)[C@H](CC)C)=O)CC%10=CC=CC=C%10)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C
Biological Activity: Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Macupatide | 99.99% | Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Roell W, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. Mol Metab. 2026;103:102298. [Content Brief]
- [2]. Mari A, et al. Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care. 2025;48(9):1622-1627. [Content Brief]
Keywords
